In this Point/Counterpoint, Drs. Bhat and Punnen argue that active surveillance can be beneficial for patients with intermediate-risk prostate cancer.
Sanoj Punnen, MD, MAS
Advertisement
Articles by Sanoj Punnen, MD, MAS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Accepts NDA for Daraxonrasib in Pretreated Metastatic Pancreatic Cancer
2
RASolute 302 and the Future of Pancreatic Cancer Treatment: Paul Oberstein, MD, on the KRAS Breakthrough
3
Mapping the Full CAR T-Cell Journey in DLBCL From Referral to Survivorship
4
Balancing Oncologic Outcomes With Patient Priorities in Prostate Cancer Care
5